| Document |
Document Title |
|
WO/2021/113266A1 |
Disclosed herein are methods, pharmaceutical combinations, and dosage combinations for the prevention or treatment of cognitive disorders with the administration of a therapeutic effective amount of trapidil, a derivative, a metabolite, ...
|
|
WO/2021/111311A2 |
The present invention provides novel adamantane derivatives as inhibitors of a focal adhesion kinase, pharmaceutically acceptable salts thereof, stereoisomer thereof, a hydrate or solvate thereof, and a pharmaceutical composition compris...
|
|
WO/2021/113689A1 |
The present disclosure provides SPAK/OSR inhibitors. In certain embodiments, the compounds of the disclosure can be used to treat, ameliorate, and/or prevent certain cancers in a subject.
|
|
WO/2021/113808A1 |
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating dis...
|
|
WO/2021/108683A1 |
The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological proces...
|
|
WO/2021/104363A1 |
Disclosed are a composition containing an aromatic heterocyclic compound in an amorphous form, and a preparation method therefor and a use thereof. Specifically, disclosed is a composition containing a compound of formula (1) and a carri...
|
|
WO/2021/102569A1 |
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
|
|
WO/2021/102567A1 |
The synthesis of a range of pentylbezene- 1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors....
|
|
WO/2021/106947A1 |
Provided are a compound represented by formula (1) or a pharmacologically acceptable salt thereof, and an antitrypanosomal drug containing the same as an active ingredient. In formula (1), X is NH or CH2, R1 is a hydrogen atom, an alkoxy...
|
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
|
WO/2021/105908A1 |
The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R1a, R2a, R3a, A1, A2, A3, R1b, R2b, R3b, B1, and B2 are as set forth in the specification, as well as to methods for their preparat...
|
|
WO/2021/107657A1 |
The present invention relates to a novel quinazoline derivative compound and a use thereof and, more specifically, to a novel quinazoline derivative compound of the following chemical formula 1 having inhibitory activity against a bromod...
|
|
WO/2021/103256A1 |
The present invention provides a continuous synthesis method for a 2-chloropyrimidine-4-formic acid compound. The 2-chloropyrimidine-4-formic acid compound has the structure as shown in formula I: (I), in formula I, R1 and R2 are indepen...
|
|
WO/2021/098859A1 |
An aza seven-membered ring inhibitor, and a preparation method therefor and use thereof. Specifically, a compound has a structure represented by formula (I). Disclosed are a preparation method for the compound and the use of same as a KR...
|
|
WO/2021/101264A1 |
The present invention relates to an azobenzene compound, a hologram recording composition comprising same, a hologram recording medium, a hologram recording material using same, and a method for hologram recording or hologram re-recordin...
|
|
WO/2021/101255A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to: an organic compound having excellent heat resistance, carrier transport capability, luminescence ca...
|
|
WO/2021/099842A1 |
Provided herein are pentafluorobenzenesulfonamide compounds of Formula (I), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases. These compounds are covalent small mol...
|
|
WO/2021/097110A1 |
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2021/097190A1 |
Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and...
|
|
WO/2021/097054A1 |
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and c...
|
|
WO/2021/092262A1 |
The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 an...
|
|
WO/2021/088742A1 |
A substituted thiazole aromatic ring-based compound and a preparation method therefor, a herbicidal composition and use thereof. The substituted thiazole aromatic ring-based compound is as shown in general formula (I), wherein Y represen...
|
|
WO/2021/090061A1 |
Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE), by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compo...
|
|
WO/2021/056922A9 |
The invention belongs to the technical field of pesticides and specifically relates to an aryl sulfide containing a benzylamine structure, a synthesis method therefor, and an application thereof. The aryl sulfide is denoted as compound I...
|
|
WO/2021/088616A1 |
Provided are a crystal form of elagolix acid sulfate, a preparation thereof and an application thereof. Specifically, the crystal form has an improved purification effect; in addition, the preparation method is simple and easy to impleme...
|
|
WO/2021/088975A1 |
Use of a compound in preventing or treating a graft versus host disease (GVHD), especially use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in preparing a drug for preventing or treating GVHD.
|
|
WO/2021/083185A1 |
Provided is a pyrimidine-containing piperidinamine compound, the structure of which is shown in general formula I: the definition of each substituent in the formula is shown in the description. The provided compound shows good insecticid...
|
|
WO/2021/083186A1 |
Disclosed is a piperidinamine compound containing fused ring pyrimidine, the structure of the compound being as shown in general formula L: the definition of each substituent in the formula is shown in the description. The compound of th...
|
|
WO/2021/083879A1 |
The invention relates to compounds according to the general formula (1), to their use for producing a medicament, in particular for the treatment of bromodomain-related diseases, such as cancers.
|
|
WO/2021/083554A1 |
The present invention relates to a new intermediate useful in the synthesis of elagolix, to a process for obtaining said intermediate, to the use of said intermediate for preparing elagolix, and to a process for preparing elagolix making...
|
|
WO/2021/082997A1 |
An amide compound containing a substituted acetophenone structure fragment, having a structure shown as general formula I. Please see the description for the definitions of substituents in the formula. The compound has a broad-spectrum b...
|
|
WO/2021/085389A1 |
The present invention addresses the problem of providing: a 2,6-dioxo-3,6-dihydropyrimidine compound which has excellent bactericidal activity, is safe, and can be industrially advantageously synthesized; and an agricultural and horticul...
|
|
WO/2021/080282A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/080980A1 |
Disclosed are compounds of formula (I) below or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof: (I), in which each of variables each of variables R, R1, R2, X1, X2, X3 and n is defined herein. Also disclosed is...
|
|
WO/2021/080929A1 |
The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitor...
|
|
WO/2021/076691A1 |
Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as define...
|
|
WO/2021/075691A1 |
The present invention relates to a pyrimidine derivative, a method of preparing same, and a pharmaceutical composition for preventing or treating cancer, comprising the pyrimidine derivative as an effective component, wherein the derivat...
|
|
WO/2021/073494A1 |
The present invention relates to the salts of a compound and the crystalline forms thereof. More specifically, the present invention belongs to the pharmaceutical field, and provides the pharmaceutically acceptable salts of the compound ...
|
|
WO/2021/075775A1 |
The present invention relates to a novel compound having excellent carrier transport ability, light-emitting ability, and thermal stability, and to an organic electroluminescent device comprising same in one or more organic material laye...
|
|
WO/2021/070150A1 |
The present invention relates to an inhalable composition comprising a therapeutically effective dosage amount of compound (I), 2-{4-[(2S)-1,1-difluoro-2-hydroxypropyl]phenyl}-N-{4-[3-(2-e
thylphenyl) pyrazine-2-yl]phenyl}acetamide or a ...
|
|
WO/2021/068950A1 |
Disclosed in the present invention are an amide compound and the medical use thereof as a STING inhibitor. Specifically, disclosed is a compound represented by formula I or formula II, or a pharmaceutically acceptable salt or ester or so...
|
|
WO/2021/064561A1 |
An improved process for the preparation of Elagolix Sodium having the structural formula (I). The present invention relates to highly pure compound of formula (VI) as a solid which is useful in the preparation of Elagolix sodium. The pre...
|
|
WO/2021/063856A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/063821A1 |
The present invention covers pyrimidinedione derivatives of general formula (I) : (I), in which R1, R2, R4, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ...
|
|
WO/2021/063207A1 |
Provided are a compound as shown in formula (I), which formula is as follows, and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof,...
|
|
WO/2021/062559A1 |
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...
|
|
WO/2021/059017A1 |
Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine...
|
|
WO/2021/061695A1 |
Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatmen...
|
|
WO/2021/057009A1 |
The present invention provides an improved N-heterocyclic planar optical coupling output material. The general structural formula of the N-heterocyclic planar optical coupling output material is R1-R2-R1. The structural formula of the sy...
|
|
WO/2021/059287A1 |
A method of oxygenating a benzylic C-H bond is provided. The method comprises light induced activation of an initiator and subsequent reaction with oxygen, resulting in the formation of free radicals. Subsequently, free radicals catalyze...
|
